Stenbocki maja fassaad_allikas Riigikantselei.jpg
Stenbocki maja fassaad
“Making it possible for all who wish for it to get vaccinated against COVID-19 is a priority for the Government,” said the Prime Minister, Kaja Kallas. “These additional doses are an important support from the European Union to Estonia as it is fighting the pandemic. Every dose of the vaccine that reaches Estonia is necessary, helping more Estonian people to protect themselves and others from COVID-19 faster. Our objective is to reach a point where 70 percent of Estonian residents have the opportunity to get vaccinated by the end of the summer. It is also important that all European Union member states reach their vaccination goals, and the solidarity in distributing of vaccines has an important role to play here,” stressed Kallas.
The vaccine manufacturer Pfizer/BioNTech has managed to produce more vaccines than planned during the first quarter. As a result of the negotiations held with the European Union, the vaccine manufacturer is delivering 10 million doses of the vaccine earlier than planned, starting from April. “Unfortunately, the situation with the spread of the virus is worsening in many European countries, which is why the negotiations over distributing the additional doses were also very difficult. The agreement that was reached is favourable for Estonia, as we are getting close to twice as many doses than the size of our population would have indicated for us,” said the Minister of Health and Labour, Tanel Kiik. “I would like to thank all parties that contributed to the negotiations, and the member states of the European Union for a solidarity agreement.”
Last week, on March 25, the heads of states and governments of the European Union tasked the member states’ permanent representatives in Brussels with coming to an agreement about how the additional 10 million doses of the Pfizer/BioNTech vaccine will be distributed.
Seven million of the ten million additional doses of the COVID-19 vaccine will be divided proportionally between the member states, according to the share of the corresponding state’s population in the total population of the EU (pro rata). On the basis of that, Estonia will get close to 21,000 doses. The remaining three million doses are distributed between the five member states who earlier did not order the full pro rata volume from the main or supplementary agreement with Pfizer/BioNTech – Estonia is among them, having taken the full amount from the main agreement, but less from the supplementary agreement. Of the remaining three million vaccine doses, Estonia will receive more than 41,000 additional doses. In addition to Estonia, extra doses will go to Bulgaria, Croatia, Latvia, and Slovakia.
Altogether, there are vaccines from eight vaccine manufacturers in the joint European Union vaccine portfolio -- Pfizer/BioNTech, Moderna, AstraZeneca, Janssen Pharmaceutica NV, CureVac, Sanofi, Novavax, Valneva. To date, Estonia has joined five advance purchase agreements in the joint European Union COVID-19 vaccine procurement: Pfizer/BioNTech, Moderna, AstraZeneca, Janssen Pharmaceutica NV, and CureVac. With the Valneva agreement that was added to the joint European Union vaccine portfolio, Estonia has the possibility to acquire 4,568,810 doses of vaccine for 2,434,406 persons in total.
The objectives of the COVID-19 vaccination are to protect risk groups who are at a higher risk for infection or more severe progression of the COVID-19 disease if they get infected, prevent and reduce the infections and deaths caused by COVID-19, reduce the burden on the healthcare system and the economy, and ensure the normal functioning of the society.